Literature DB >> 33082393

Session-specific effects of the Metacognitive Group Training for Obsessive-Compulsive Disorder: significant results for thought control.

Franziska Miegel1, Barbara Cludius2, Birgit Hottenrott3, Cüneyt Demiralay3, Lena Jelinek3.   

Abstract

The investigation of the session-specific effects is central for the understanding of psychological interventions. For the present study, we investigated the session-specific effects of the Metacognitive Group Training for Obsessive-Compulsive Disorder (MCT-OCD), which was revised based on data of a pilot study. Thirty-four outpatients with OCD participated in the MCT-OCD once a week over 8 weeks. Different metacognitive beliefs (e.g., thought control) and cognitive beliefs (e.g., intolerance of uncertainty), OC symptoms, as well as associated comorbid symptoms were assessed before and after each session. Linear mixed effects models showed that patients' obsessions and compulsions, thought control, the belief of being well informed about the disorder, and action fusion improved over the course of the training. The only session-specific effect emerged for thought control, which improved immediately after the respective module. We were able to replicate the findings of the pilot study and thus corroborate the session-specific effect of the module targeting thought control. Moreover, we generated information on the mode of action of the individual modules of the MCT-OCD that allows a more in-depth evaluation of the intervention. Notably, we were able to eliminate the adverse effects of the pilot version of the MCT-OCD.Trial Registration: German Clinical Trials Register (Deutsches Register Klinischer Studien [DRKS]; DRKS-ID: DRKS00013539; registration date: 22/02/2018).

Entities:  

Mesh:

Year:  2020        PMID: 33082393      PMCID: PMC7576173          DOI: 10.1038/s41598-020-73122-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  13 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

Review 2.  Understanding how and why psychotherapy leads to change.

Authors:  Alan E Kazdin
Journal:  Psychother Res       Date:  2009-07

3.  Cognitive assessment of obsessive-compulsive disorder. Obsessive Compulsive Cognitions Working Group.

Authors: 
Journal:  Behav Res Ther       Date:  1997-07

4.  Session-specific effects of the Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD).

Authors:  Franziska Miegel; Barbara Cludius; Birgit Hottenrott; Cüneyt Demiralay; Anna Sure; Lena Jelinek
Journal:  Psychother Res       Date:  2019-05-09

5.  The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; P Delgado; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

6.  Psychometric validation of the Obsessive Beliefs Questionnaire and the Interpretation of Intrusions Inventory: Part I.

Authors: 
Journal:  Behav Res Ther       Date:  2003-08

7.  Does the addition of cognitive therapy to exposure and response prevention for obsessive compulsive disorder enhance clinical efficacy? A randomized controlled trial in a community setting.

Authors:  Neil A Rector; Margaret A Richter; Danielle Katz; Michelle Leybman
Journal:  Br J Clin Psychol       Date:  2018-07-08

8.  Assessment and Selection of Competing Models for Zero-Inflated Microbiome Data.

Authors:  Lizhen Xu; Andrew D Paterson; Williams Turpin; Wei Xu
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Metacognitive Training for Obsessive-Compulsive Disorder: a study protocol for a randomized controlled trial.

Authors:  Franziska Miegel; Cüneyt Demiralay; Steffen Moritz; Janina Wirtz; Birgit Hottenrott; Lena Jelinek
Journal:  BMC Psychiatry       Date:  2020-07-06       Impact factor: 3.630

10.  Understanding and misunderstanding randomized controlled trials.

Authors:  Angus Deaton; Nancy Cartwright
Journal:  Soc Sci Med       Date:  2017-12-25       Impact factor: 5.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.